for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Adverum Biotechnologies Inc

ADVM.OQ

Latest Trade

13.39USD

Change

-0.03(-0.22%)

Volume

272,926

Today's Range

13.08

 - 

13.46

52 Week Range

7.36

 - 

26.98

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
13.42
Open
13.46
Volume
272,926
3M AVG Volume
20.90
Today's High
13.46
Today's Low
13.08
52 Week High
26.98
52 Week Low
7.36
Shares Out (MIL)
97.48
Market Cap (MIL)
1,305.23
Forward P/E
-10.24
Dividend (Yield %)
--

Next Event

Q4 2020 Adverum Biotechnologies Inc Earnings Release

Latest Developments

More

Adverum Biotechnologies Completes Patient Enrollment for INFINITY Phase 2 Trial of ADVM-022 in DME, Provides 2021 Business Outlook

Adverum Biotechnologies Says Q3 Loss Per Share $0.31

Adverum Biotechnologies Announces $200 Million Public Offering Of Common Stock

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Adverum Biotechnologies Inc

Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company targeting unmet medical needs for serious ocular and rare diseases. The Company is evaluating its gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of its lead indication, wet age-related macular degeneration. It has collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize gene therapy products (AVA-311) for ophthalmic diseases. The Company develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its capabilities include clinical development, vector discovery, and in-house manufacturing, specifically in process development, assay development and current Good Manufacturing Practices (cGMP) quality control.

Industry

Biotechnology & Drugs

Contact Info

800 Saginaw Drive

REDWOOD CITY, CA

94063

United States

+1.650.2726269

https://adverum.com/

Executive Leadership

Patrick Machado

Independent Chairman of the Board

Leone D. Patterson

President

Laurent Fischer

Chief Executive Officer, Director

Thomas Leung

Chief Financial Officer

Angela Thedinga

Chief Technology Officer

Key Stats

2.10 mean rating - 10 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2017

-1.290

2018

-1.180

2019

-1.010

2020(E)

-1.308
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
2.81
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-29.09
Return on Equity (TTM)
-27.70

Latest News

Latest News

BRIEF-Adverum Biotech Announces New Mid-Stage Trial For ADVM-022 In Diabetic Macular Edema

* ADVERUM BIOTECHNOLOGIES ANNOUNCES NEW INFINITY PHASE 2 TRIAL FOR ADVM-022 IN DIABETIC MACULAR EDEMA, REPORTS RECENT BUSINESS PROGRESS AND FIRST QUARTER 2020 FINANCIAL RESULTS

BRIEF-Adverum Biotech Reports Positive Interim Data From Cohorts 1-3 Of Optic Phase 1 Trial Of Advm-022 Intravitreal Gene Therapy For Wet AMD

* ADVERUM BIOTECHNOLOGIES REPORTS POSITIVE INTERIM DATA FROM COHORTS 1-3 OF OPTIC PHASE 1 TRIAL OF ADVM-022 INTRAVITREAL GENE THERAPY FOR WET AMD

BRIEF-Adverum Biotechnologies Doses First Patient In Cohort 4 Of OPTIC Phase 1 Clinical Trial Of ADVM-022

* ADVERUM BIOTECHNOLOGIES DOSES FIRST PATIENT IN COHORT 4 OF OPTIC PHASE 1 CLINICAL TRIAL OF ADVM-022 INTRAVITREAL GENE THERAPY FOR WET AMD Source text for Eikon: Further company coverage:

BRIEF-Adverum Biotechnologies On April 16, Increased Size Of Board To Ten Members

* ADVERUM BIOTECHNOLOGIES INC - ON APRIL 16, INCREASED SIZE OF BOARD TO TEN MEMBERS Source text: [https://bit.ly/2wSTG7V] Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Adverum Biotechnologies Reports Q4 Loss Per Share $0.29

* ADVERUM BIOTECHNOLOGIES REPORTS RECENT BUSINESS PROGRESS AND FOURTH QUARTER 2019 FINANCIAL RESULTS

BRIEF-Adverum Biotechnologies Announces $100 Mln Public Offering Of Common Stock

* ADVERUM BIOTECHNOLOGIES ANNOUNCES $100 MILLION PUBLIC OFFERING OF COMMON STOCK

BRIEF-Adverum Biotechnologies Reports New Interim Data From Cohorts 1 & 2 Of Optic Phase 1 Trial Of ADVM-022

* ADVERUM BIOTECHNOLOGIES REPORTS NEW INTERIM DATA FROM COHORTS 1 AND 2 OF OPTIC PHASE 1 TRIAL OF ADVM-022 INTRAVITREAL GENE THERAPY FOR WET AMD AT ANGIOGENESIS, EXUDATION, AND DEGENERATION 2020

BRIEF-Adverum Biotechnologies Reports Q1 Loss Per Share $0.30

* ADVERUM BIOTECHNOLOGIES REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Adverum Biotechnologies Announces Leadership Changes

* BOARD AND AMBER SALZMAN, CHIEF EXECUTIVE OFFICER MADE A MUTUAL DETERMINATION THAT SALZMAN STEP DOWN

BRIEF-Adverum Biotechnologies Announces Long-Term Preclinical Efficacy Data On ADVM-022 Gene Therapy In Wet AMD

* ADVERUM BIOTECHNOLOGIES ANNOUNCES LONG-TERM PRECLINICAL EFFICACY DATA ON ADVM-022 GENE THERAPY IN WET AMD

BRIEF-Adverum Biotechnologies Q4 Loss Per Share $0.32

* ADVERUM BIOTECHNOLOGIES REPORTS FOURTH QUARTER 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Adverum Biotechnologies Prices $60 Mln Public Offering Of Stock

* ADVERUM BIOTECHNOLOGIES ANNOUNCES PRICING OF $60 MILLION PUBLIC OFFERING OF COMMON STOCK

BRIEF-Adverum Biotechnologies Announces Proposed Public Offering

* ADVERUM BIOTECHNOLOGIES ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Adverum Biotechnologies Extends Collaboration Agreement With Editas Medicine

* ANNOUNCES EXTENSION OF ITS COLLABORATION AGREEMENT WITH EDITAS MEDICINE INC

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up